DOCSLIB.ORG

Program Book

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Program Book Welcome to Porto and BioIron 2009 We express our appreciation to both Portos: the city and our local chair Graça Porto, who contributed so much to the preparation of the meeting. On behalf of the organizers we also thank you for coming to Porto 200 years after it became a battleground of Europe divided by men who sought to establish their power by war. Science has counteracted that notion of power, by promoting shared knowledge as a unifying force that transcends these artificial divisions and now encompasses women as equals. Let us make Bioiron 2009 a successful forum for scientific exchange and collegial friendship between scientists from all over the globe! Pierre Brissot, IBIS President Tomas Ganz, IBIS Elect-President Maria de Sousa, Co-Chairman of the Local Organizing Committee 1 2 Table of Contents Schedule at a Glance ..................................................................... Inside Front Cover IBIS Board of Directors & Committees.....................................................................4 General Meeting Information.....................................................................................5 Social Activities .........................................................................................................8 Program Schedule ....................................................................................................10 Invited Speaker Abstracts and Bios .........................................................................50 Podium Abstracts .....................................................................................................64 Poster Abstracts........................................................................................................95 Alphabetical Index of Authors by Presentation.....................................................188 Acknowledgements........................................................................Inside Back Cover 3 2009 IBIS Board of Directors & Committees OFFICERS Pierre Brissot, MD, President DIRECTORS Tomas Ganz, MD, PhD, President-Elect Robert Fleming, MD Paolo Arosio, PhD, Secretary Prem Ponka, MD, PhD Caroline Philpott, MD, Treasurer Graça Porto, MD, PhD Grant A. Ramm, PhD EXECUTIVE OFFICE Kathryn Robson, PhD Wendy J. Weiser, Executive Director Guenter Weiss, MD Sue O’Sullivan, Associate Director International Scientific Committee Local Organizing Committee PRESIDENT CHAIRS Pierre Brissot, MD Graça Porto, MD, PhD Maria de Sousa, MD, PhD MEMBERS Paolo Arosio, PhD MEMBERS Tomas Ganz, MD, PhD Sérgio de Almeida, PhD Robert Fleming, MD Idalina Beirão, MD Jerry Kaplan, PhD Carla Sofia Cardoso, PhD Caroline Philpott, MD Ana Paula Correia, MD Prem Ponka, MD, PhD Eugénia Cruz, MD, PhD Graça Porto, MD, PhD Hal Drakesmith, PhD Grant Ramm, PhD Maria Salomé Gomes, PhD Kathryn Robson, PhD Pedro Moradas-Ferreira, PhD Guenter Weiss, MD José Fraga, MD Guenther Winkelmann, PhD José Moura, MD Joana Palha, PhD Jorge Pinto, PhD Local Organizations Alexandre Quintanilha, PhD FCT, Portuguese Science and Technology Conceição Rangel, PhD Foundation Pedro Rodrigues, PhD IBMC, Institute for Molecular and Cellular Ana Tomás, PhD Biology Jorge Vieira, PhD 4 2009 IBIS General Meeting Information Venue Porto Congress Center Alfândega Rua Nova da Alfândega Edificio da Alfândega 4050-430 Porto, Portugal Phone: +351 223 403 000 Fax: +351 223 403 099 Website: www.amtc.pt/congresso Dates of the Congress June 7 – 11, 2009 On Sunday, June 7, registration will open at 14:00 and the Welcome Reception (Get-Together Party) will begin at 19:00. The congress will begin with the Opening Ceremony at the Porto Congress Center Alfândega on Monday, June 8, at 09:00 and concludes with the Closing Ceremony at the Congress Center on Thursday, June 11, at 17:00. Language The official language of the congress is English. Map of Porto 5 2009 IBIS General Meeting Information Money The local currency is the Euro (€). Banks in Portugal are open Monday – Friday, 08:30 – 15:00 (Banks at the airports are open 08:00 – 20:00). Portugal also has an extensive network of cash dispensers (labeled Multibanco) that operate 24 hours a day. Shopping The most traditional shopping area is Rua Santa Catarina, along with the narrow streets going up and down from the city center till Ribeira, by the Douro riverside. Several shopping centers, in and around Porto, are open daily until 23:00. Besides the major international franchising and brands, national textiles, leather, pottery, shoes, crystal, wines and gold handcraft can be found in the shops. Visas All non-EU citizens should check if it is necessary to obtain a visa, which can be obtained at the Portuguese Embassy or Consulate in their own country. A list of countries that require a visa to Portugal is given on the following website: www.wordtravels.com/Travelguide/Countries/Portugal/Visa Local Time The local time in Portugal is the Greenwich Mean Time, which is the same as in London. GMT + 1 Hour (Western Europe Daylight/Summer Time) Electricity Supply: 220 V Emergency Number 112 Registration / Information Desk The registration / information desk is located in the Porto Congress Center Alfândega. Sunday, June 7th 14:00 – 20:00 Monday, June 8th 08:00 – 18:30 Tuesday, June 9th 08:00 – 14:30 Wednesday, June 10th 08:00 – 18:15 Thursday, June 11th 08:00 – 18:15 Registration fee for participant includes: • Admission to Opening Ceremony and all scientific sessions • Admission to the exhibition area • Congress materials (congress bag, badge, certificate of attendance) • Abstract Book • Coffee breaks, lunch, and afternoon refreshments • Welcome Reception on Sunday, June 7, 2009 • Closing Ceremony and scientific sessions on Thursday, June 11, 2009 Registration fee for accompanying person includes: • Admission to the exhibition area • Coffee breaks, lunch, and afternoon refreshments • Welcome Reception on Sunday, June 7, 2009 • Closing Ceremony on Thursday, June 11, 2009 6 2009 IBIS General Meeting Information Name Badges Attendees are requested to wear their name badges while at the meeting. Presenters – Slide Review Room The Slide Review Room is in Miragaia in the Porto Congress Center Alfândega. Presentations must be delivered the day prior to your presentation. Those presenting on Monday, June 8th should submit their presentation on Sunday. Sunday, June 7th 15:00 – 20:00 Monday, June 8th 08:00 – 18:30 Tuesday, June 9th 08:00 – 14:30 Wednesday, June 10th 08:00 – 18:15 Thursday, June 11th 08:00 – 18:15 Poster Sessions Posters will be available for viewing throughout the entire meeting; however, presentations will occur during the following times/sessions: Poster Session I – June 8th 14:00 – 15:15 Poster Session II – June 10th 14:00 – 15:15 Poster Session III – June 11th 14:00 – 15:15 Tourist Information Tourist information is available from your hotel concierge or at the Porto Congress Center Alfândega information desk. Lunch Lunch will be served Monday though Thursday in Noble Hall. Cancellations and Refunds Cancellations must be made in writing to the BioIron 2009 Office. Cancellations received after May 1, 2009 will be considered at the discretion of the Organizing Committee at the conclusion of the meeting. Dress The meeting dress is business casual throughout the conference, except for the Gala Dinner, which is formal dress. First Aid Medical doctors can be called by your hotel in case of emergencies or by the Porto Congress Center Alfândega. Special Needs (including dietary needs / allergies) If you have specific needs to facilitate your comfort during the conference (i.e. wheelchair access, dietary, auditory or other assistance), all concerns should be addressed at the conference registration / information desk. In general, soups in Portugal are very good and are not prepared with milk. Fish is generally served with potatoes and vegetables; however, some codfish dishes (popular bacalhau dishes) are prepared with milk, so please beware. Liability BioIron will not be liable for illness, accidents or thefts suffered by participants or accompanying persons during the conference or their stay in Portugal. 7 2009 IBIS Social Activities Welcome Reception (Get-Together Party) Venue: Alfândega Mooring by the Douro Date: Sunday, June 7, 2009 Time: 19:00 – 21:00 Cost: Registration fee covers cost of participant and guest. Attire: Casual Dress The Congress Center is located at “Alfândega”, an imposing former Customs House standing on an artificial platform and a remarkable example of nineteenth century engineering and iron architecture. The Welcome Reception will be held at the “Salão Nobre” or noble room, which extends to the dock thus offering, in favorable weather conditions, a splendid view to the Douro River. Gala Dinner Venue: Palácio da Bolsa Date: Thursday, June 11, 2009 Departure: 19:30 from all official congress hotels Time: 20:30 Cost: 90 USD Attire: Formal Dress The BioIron 2009 Award Ceremony will be held during the Gala Dinner. The “Palácio da Bolsa” is considered one of the most beautiful buildings in Porto and one of the richest in Portugal, as well as a favorite place for most relevant social, cultural and political events linked to the life of the city. It was built as a trade center in middle nineteenth century with the great investment and dedication of Porto merchandisers. The Gala Dinner and Award Ceremony of Bioiron 2009 is organized in this beautiful environment and is certainly a program not to miss. Sightseeing For sightseeing tours you can contact Skyros-Congressos (Phone: +351 22 616 54 50; Email: [email protected])
Load more

Recommended publications
  • CHEMDNER-Patents: Chemical Entity Annotation Manual
    CHEMDNER-patents: Chemical Entity annotation manual Version 2.0 (May 2015) This document describes the annotation guidelines used for the construction of the annotations chemical mentions (CEM – Chemical Entity Mention) of the CHEMDNER-patents corpus. These annotation guidelines were generated based on the CHEMDNER 2013 task exclusively focused on chemical entities extracted from papers. Thus, annotation guidelines were adapted to mine patents with a stronger focus on identifying any wide definition of chemical terms rather than in obtaining highly refined chemical mentions that can be univoquely translated into a chemical structure. The reason for this subtle refinement resides in the fact that patents contain very wide, general chemical mentions to describe the different substituents of the general Markush formula. Discarding this kind of mentions would prevent future applications (e.g. deconvolution and interpretation of Markush formula) of the CHEMDNER-patents corpus. However, no attempt is made to establish Markush structure relation: establishing meaningful correlations between the Markush formula and substituents. Thus, two related CEMs that are clearly separated as different entities in the text will be annotated as two different CEMs; although the meaning of one of them can be linked to the other one. This guide provides the basic details of the CEM task and the conventions that should be followed during the corpus construction process. The annotation guidelines were refined after iterative cycles of annotations of sample documents based on direct suggestions made by the curators as well as through the observation of inconsistencies detected when comparing the results provided by different curators. Some participating teams provided feedback to improve the documentation after the release of the first sample set prepared for the CHEMDNER 2013 task.
    [Show full text]
  • José De Figueiredo Seixas Vida E Obra
    Geometria nos traçados urbanos de fundação portuguesa o Tratado da Ruação de José Figueiredo Seixas JOSÉ DE FIGUEIREDO SEIXAS VIDA E OBRA JOSÉ DE FIGUEIREDO SEIXAS VIDA E OBRA 52 Geometria nos traçados urbanos de fundação portuguesa o Tratado da Ruação de José Figueiredo Seixas JOSÉ DE FIGUEIREDO SEIXAS VIDA E OBRA José de Figueiredo Seixas não é de maneira nenhuma um nome corrente nem sequer sonante no panorama arquitectónico e/ou artístico português. A referência ao seu nome não é prática corrente e está por fazer o levantamento exaustivo do seu percurso pessoal e profissional. Não fazendo parte dos nossos objectivos levar a cabo um estudo biográfico sobre o autor do Tratado da Ruação, que consideramos no entanto urgente acontecer, a investigação levada a cabo neste capítulo reporta quase exclusivamente à consulta de fontes indirectas. Apesar de sintética encontra-mos alusão ao seu nome em diversos dicionários e enciclopédias. Sousa Viterbo1 e José Manuel Pedreirinho2 constituem leitura obrigatória neste capítulo. O primeiro refere-o como architecto da igreja da Ordem Terceira do Carmo, cuja primeira pedra foi lançada a 29 de agosto de 1756 3, remetendo para a sua fonte Francisco Patricio, Resumo histórico da fundação e desenvolvimento da venerável Ordem Terceira de Nossa Senhora do Monte do Carmo no Porto 4. O segundo escreve acerca dele que é natural de Viseu, desconhe-se-se a data do seu nascimento, morre no Porto em 1773. Sabe-se que trabalhou como pintor sob a direcção de Nicolau Nasoni (trabalhou na Sé do Porto, 1734, Vila Real, 1745, Igreja dos Clérigos no Porto) e como arquitecto, sendo talvez o autor da Capela do Solar de Mateus (1743) e da fachada da Capela Nova (1753), ambas em Vila Real e muito na linha das obras de Nasoni.
    [Show full text]
  • Comparative Study of Deferiprone Versus Deferiprone with Deferasirox
    BANGLADESH J CHILD HEALTH 2019; VOL 43 (3) : 152-156 Comparative study of Deferiprone versus Deferiprone with Deferasirox as iron chelation therapy in Thalassemic children SYEDA JARKA JAHIR1, SAYEEDA ANWAR2, AKM AMIRUL MORSHED3, AFIQUL ISLAM4, KABIRUL ISLAM5 Abstract Background: Combination therapy of Deferiprone (DFP) with Deferasirox (DFX) is an efficacious and safe modality to reduce serum ferritin in multi-transfused children with thalassemia. Objectives: To compare the efficacy of Deferiprone versus Deferiprone with Deferasirox as iron chelation therapy of transfusion dependent thalassemia children. Materials and Methods: A non-randomized control clinical trial was done in department of Pediatric Hematology and Oncology, Dhaka Medical College Hospital and Bangladesh Thalassemia Hospital in Dhaka during the period of October 2016 to September 2017. Thirty children with transfusion dependent thalassemia major between 3 to 12 years of age were included in each group in this study. Children with thalassemia minor, after splenectomy, with comorbidities and on other iron chelation therapy were excluded from this study. Results: Among total enrolled 60 cases in this study, initial mean serum ferritin level was 3397.48 ± 774.48 ng/ml in DFP-monotherapy group and 3413.70 ± 1114.05ng/ ml in DFP-DFX combination group. Mean serum ferritin level at 6thmonth was found 2730.63 ± 839.91ng/ml in DFP-monotherapy group and 1654.20 ± 934.90 ng/ml in DFP-DFX-combination group which shows rapid reduction of serum ferritin level in DFP-DFX-combination group. 12 (40.0%) patients had arthralgia in DFP- monotherapy group and 5(16.7%) patients had vomiting in DFP-DFX-combination group.
    [Show full text]
  • MEDICATION GUIDE FERRIPROX (Feh' Ri Prox) (Deferiprone) Oral
    MEDICATION GUIDE FERRIPROX® (Feh’ ri prox) (deferiprone) oral solution What is the most important information I should know about FERRIPROX? FERRIPROX can cause serious side effects, including a very low white blood cell count in your blood. One type of white blood cell that is important for fighting infections is called a neutrophil. If your neutrophil count is low (neutropenia), you may be at risk of developing a serious infection that can lead to death. Neutropenia is common with FERRIPROX and can become severe in some people. Severe neutropenia is known as agranulocytosis. If you develop agranulocytosis, you will be at risk of developing serious infections that can lead to death. Your healthcare provider should do a blood test before you start FERRIPROX and weekly during treatment to check your neutrophil count. If you develop neutropenia, your healthcare provider should check your blood counts every day until your white blood cell count improves. Stop taking FERRIPROX and get medical help right away if you develop any of these symptoms of infection: •fever • sore throat or mouth sores • flu-like symptoms • chills and severe shaking. See “What are the possible side effects of FERRIPROX?” for more information about side effects. What is FERRIPROX? FERRIPROX is a prescription medicine used to treat people with thalassemia syndromes who have iron overload from blood transfusions, when current iron removal (chelation) therapy does not work well enough. It is not known if FERRIPROX is safe and effective: • to treat iron overload due to blood transfusions in people with any other type of anemia that is long lasting (chronic) • in children Who should not take FERRIPROX? Do not take FERRIPROX if you are allergic to deferiprone or any of the ingredients in FERRIPROX.
    [Show full text]
  • Current Biomedical Use of Copper Chelation Therapy
    International Journal of Molecular Sciences Review Current Biomedical Use of Copper Chelation Therapy Silvia Baldari 1,2, Giuliana Di Rocco 1 and Gabriele Toietta 1,* 1 Department of Research, Advanced Diagnostic, and Technological Innovation, IRCCS Regina Elena National Cancer Institute, via E. Chianesi 53, 00144 Rome, Italy; [email protected] (S.B.); [email protected] (G.D.R.) 2 Department of Medical Surgical Sciences and Biotechnologies, University of Rome “La Sapienza”, C.so della Repubblica 79, 04100 Latina, Italy * Correspondence: [email protected]; Tel.: +39-06-5266-2604 Received: 9 January 2020; Accepted: 4 February 2020; Published: 6 February 2020 Abstract: Copper is an essential microelement that plays an important role in a wide variety of biological processes. Copper concentration has to be finely regulated, as any imbalance in its homeostasis can induce abnormalities. In particular, excess copper plays an important role in the etiopathogenesis of the genetic disease Wilson’s syndrome, in neurological and neurodegenerative pathologies such as Alzheimer’s and Parkinson’s diseases, in idiopathic pulmonary fibrosis, in diabetes, and in several forms of cancer. Copper chelating agents are among the most promising tools to keep copper concentration at physiological levels. In this review, we focus on the most relevant compounds experimentally and clinically evaluated for their ability to counteract copper homeostasis deregulation. In particular, we provide a general overview of the main disorders characterized by a pathological increase in copper levels, summarizing the principal copper chelating therapies adopted in clinical trials. Keywords: copper; chelation therapy; therapeutic chelation; metal homeostasis; cancer; metalloproteins 1.
    [Show full text]
  • Chelation Therapy
    Corporate Medical Policy Chelation Therapy File Name: chelation_therapy Origination: 12/1995 Last CAP Review: 2/2021 Next CAP Review: 2/2022 Last Review: 2/2021 Description of Procedure or Service Chelation therapy is an established treatment for the removal of metal toxins by converting them to a chemically inert form that can be excreted in the urine. Chelation therapy comprises intravenous or oral administration of chelating agents that remove metal ions such as lead, aluminum, mercury, arsenic, zinc, iron, copper, and calcium from the body. Specific chelating agents are used for particular heavy metal toxicities. For example, desferroxamine (not Food and Drug Administration [FDA] approved) is used for patients with iron toxicity, and calcium-ethylenediaminetetraacetic acid (EDTA) is used for patients with lead poisoning. Note that disodium-EDTA is not recommended for acute lead poisoning due to the increased risk of death from hypocalcemia. Another class of chelating agents, called metal protein attenuating compounds (MPACs), is under investigation for the treatment of Alzheimer’s disease, which is associated with the disequilibrium of cerebral metals. Unlike traditional systemic chelators that bind and remove metals from tissues systemically, MPACs have subtle effects on metal homeostasis and abnormal metal interactions. In animal models of Alzheimer’s disease, they promote the solubilization and clearance of β-amyloid protein by binding to its metal-ion complex and also inhibit redox reactions that generate neurotoxic free radicals. MPACs therefore interrupt two putative pathogenic processes of Alzheimer’s disease. However, no MPACs have received FDA approval for treating Alzheimer’s disease. Chelation therapy has also been investigated as a treatment for other indications including atherosclerosis and autism spectrum disorder.
    [Show full text]
  • Review of Oral Iron Chelators (Deferiprone and Deferasirox) for the Treatment of Iron Overload in Pediatric Patients
    Review of Oral Iron Chelators (Deferiprone and Deferasirox) for the Treatment of Iron Overload in Pediatric Patients D. Adam Algren, MD Assistant Professor of Pediatrics and Emergency Medicine Division of Pediatric Pharmacology and Medical Toxicology Departments of Pediatrics and Emergency Medicine Children’s Mercy Hospitals and Clinics/Truman Medical Center University of Missouri-Kansas City School of Medicine 1 PROPOSAL The World Health Organization Model List of Essential Medicines and Model Formulary 2010 list deferoxamine (DFO) as the treatment of choice for both acute and chronic iron poisoning. The Model Formulary currently does not designate any orally administered agents for the chelation of iron. It is proposed that deferasirox be considered the oral chelator of choice in the treatment of chronic iron overload. Deferasirox is widely available recent evidence support that it is both safe and efficacious. INTRODUCTION Acute iron poisoning and chronic iron overload result in significant morbidity and mortality worldwide. Treatment of acute iron poisoning and chronic iron overload can be challenging and care providers are often confronted with management dilemmas. Oral iron supplements are commonly prescribed for patients with iron deficiency anemia. The wide availability of iron supplements and iron-containing multivitamins provide easy accessibility for both adults and children. The approach to treatment of acute iron toxicity involves providing adequate supportive care, optimizing hemodynamic status and antidotal therapy with IV deferoxamine, when indicated.1 Early following an acute ingestion gastrointestinal (GI) decontamination can be potentially beneficial. Multiple options exist including: syrup of ipecac, gastric lavage, and whole bowel irrigation (WBI). Although definitive evidence that GI decontamination decreases morbidity and mortality is lacking it is often considered to be beneficial.
    [Show full text]
  • Chelating Drug Therapy: an Update
    Open Access Austin Journal of Genetics and Genomic Research Review Article Chelating Drug Therapy: An Update Vijay Kumar1, Ashok Kumar2*, Sandeep Kumar Singh1, Manoj Kumar3, Surendra Kumar2, Dinesh Abstract 4 5 Kumar and Ragni Singh Purpose: To study the clinical effects of metal toxicity and current 1Department of Neurology, SGPGIMS, India recommendations for management, including chelation therapy, are reviewed. 2Department of Medical Genetics, SGPGIMS, India 3Department of Microbiology, SGPGIMS, India Summary: Metals are essential to many biological processes, but excess 4Department of Chemistry, Dr. R.M.L. Avadh University, of it becomes hazardous to life. These are necessary for cell growth, electron India transport chain, several enzymatic activities and response of immune systems. 5Bheem Rao Ambedkar Bihar University, India They also serve as a cofactor for several enzymes. Chelation therapy is used for clinical management of the excess of metal. However, each metal requires *Corresponding author: Ashok Kumar, Department a specific chelation agent. A chelate is a compound form between metal and a of Medical Genetics, Sanjay Gandhi Post Graduate compound that contains two or more potential ligands. A promising Fe chelator Institute of Medical Sciences, Lucknow, India is Desferrioxamine (Desferal). Penicillamine and Trientine are uses for copper Received: March 12, 2015; Accepted: April 24, 2015; chelation. Meso-2,3-Dimercaptosuccinic Acid (DMSA) and 2,3-Dimercapto- Published: April 27, 2015 Propanesulphonate (DMPS) can be used as effective chelator of mercury. Dimercaprol, edetate calcium disodium, and succimer are the three agents primarily used for chelation of lead. Conclusion: Metal toxicity remains a significant public health concern. Elimination of elevated metal ions can be achieved by proper chelation agents.
    [Show full text]
  • Study Protocol
    Long-term Safety and Efficacy Study of Deferiprone in Patients with Pantothenate Kinase-Associated Neurodegeneration (PKAN) TIRCON2012V1-EXT CLINICAL STUDY PROTOCOL EudraCT Number: 2014-001427-79 IND Number: 104880 Investigational Product: Deferiprone Development Phase: III Indication Studied: Pantothenate kinase-associated neurodegeneration (PKAN) Study Design: Multi-center, single-arm, open-label, 18-month extension of an earlier 18-month study assessing the safety and efficacy of deferiprone in patients with PKAN Sponsor: ApoPharma Inc. 200 Barmac Drive Toronto, Ontario M9L 2Z7, Canada Telephone: 1-416-749-9300 Toll-Free: 1-800-268-4623 (North America only) Fax: 1-416-401-3867 Sponsor’s Representative: Fernando Tricta, MD Vice President, Medical Affairs Tel: 1-416-401-7332 Fax: 1-416-401-3867 Version and Date of Protocol: Version 2.0, 20 AUG 2014 The information contained in this document is the property of ApoPharma Inc. and is confidential. It may be submitted to a regulatory authority, an ethics committee, or an investigator for the purpose of initiation of a clinical study. Reproduction or disclosure of this information, in whole or in part, is forbidden without the written consent of ApoPharma Inc. ApoPharma Inc. Deferiprone TIRCON2012V1-EXT Clinical Study Protocol v 2.0 SIGNATURE PAGES Sponsor We, the undersigned, hereby declare that this study will be carried out under our supervision in accordance with the methods described herein. Long-term safety and efficacy study of deferiprone in patients Study Title: with pantothenate kinase-associated neurodegeneration (PKAN) Study Code: TIRCON2012V1-EXT Version Number: 2.0 Version Date: 20 AUG 2014 Caroline Fradette, PhD Date (DD MMM YYYY) Director of Clinical Research, ApoPharma Inc.
    [Show full text]
  • Iron Chelating Agents
    Pharmacy Benefit Coverage Criteria Effective Date ............................................ 1/1/2021 Next Review Date… ..................................... 1/1/2022 Coverage Policy Number ................................ P0090 Iron Chelating Agents Table of Contents Related Coverage Resources Medical Necessity Criteria ................................... 1 Dimercaprol and Edetate Calcium Disodium FDA Approved Indications ................................... 3 Penicillamine and trientene hydrochloride Recommended Dosing ........................................ 4 Background .......................................................... 8 References ........................................................ 11 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may
    [Show full text]
  • Ferriprox, INN-Deferiprone
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Ferriprox 500 mg film-coated tablets Ferriprox 1000 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Ferriprox 500 mg film-coated tablets Each tablet contains 500 mg deferiprone. Ferriprox 1000 mg film-coated tablets Each tablet contains 1000 mg deferiprone. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet. Ferriprox 500 mg film-coated tablets White to off-white, capsule-shaped, film-coated tablets imprinted “APO” bisect “500” on one side, plain on the other. The tablet is scored. The tablet can be divided into equal halves. Ferriprox 1000 mg film-coated tablets White to off-white, capsule-shaped, film-coated tablets imprinted “APO” bisect “1000” on one side, plain on the other. The tablet is scored. The tablet can be divided into equal halves. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Ferriprox monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate. Ferriprox in combination with another chelator (see section 4.4) is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload (mainly cardiac overload) justifies rapid or intensive correction (see section 4.2). 4.2 Posology and method of administration Deferiprone therapy should be initiated and maintained by a physician experienced in the treatment of patients with thalassaemia. Posology Deferiprone is usually given as 25 mg/kg body weight, orally, three times a day for a total daily dose of 75 mg/kg body weight.
    [Show full text]
  • Cultural Landscape of the Alto Douro Wine Region Archaeological Sites
    Historic Centre of Porto The history of Porto, which is proudly known as the Cidade Association), the Ferreira Borges Market and the building known as the Alfândega Nova (New Customs Invicta (Invencible City) is profoundly linked to the River Douro, that hard to navigate river House), at the entrance to Miragaia, clearly attest to this. which curves and proudly displays its six bridges, inviting observation… of the D. Luís bridge, At the end of the middle ages, the city began to spread beyond the upper town - the Episcopal city - and the lower a cast iron structure in the 19th century style, whose higher and lower levels link the banks mercantile and trading town. From the beginning of the 14th century, the hillside once known as Olival, nowa- of the cities of Porto and Vila Nova de Gaia. Both have a history and stories to tell, both banks days named Vitória, saw a new urban dynamism, thanks to the creation of the New Jewish Quarter, in the street invite us to stop a while. where the São Bento da Vitória Monastery would eventually be built. In the 18th century the Clérigos Church, with its house and tower, paid homage to the Christian faith with its art, setting its stamp on the personality of Leaving the Monastery of Santo Agostinho da Serra do Pilar, through the top level of the bridge, we soon the place and becoming the trademark of the city. This masterpiece of baroque architecture was designed by the arrive at Porto Cathedral, the symbol of what was once the Episcopal city.
    [Show full text]